Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors

By Rubenstein Marvin   Tsui Paulus   Guinan Patrick  

Medical Oncology, Vol. 24, Iss. 4, 2007-12 ,pp. : 372-378

Humana Press, Inc

Access to resources Recommend Favorite

Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR

By Rubenstein Marvin  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1212-1218

Humana Press, Inc

Access to resources Recommend Favorite

Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2

By Rubenstein Marvin   Tsui Paulus   Guinan Patrick  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 592-599

Humana Press, Inc

Access to resources Recommend Favorite

Bcl-2/bcl-xL Bispecific Antisense Treatment Sensitizes Breast Carcinoma Cells to Doxorubicin, Paclitaxel and Cyclophosphamide

By Simões-Wüst A.P.  

Breast Cancer Research and Treatment, Vol. 76, Iss. 2, 2002-11 ,pp. : 157-166

Springer Publishing Company

Access to resources Recommend Favorite

Treatment of the T98G Glioblastoma Cell Line with Antisense Oligonucleotides Directed Toward mRNA Encoding Transforming Growth Factor-α and the Epidermal Growth Factor Receptor

By Rubenstein M.   Glick R.   Lichtor T.   Mirochnik Y.   Chou P.   Guinan P.  

Medical Oncology, Vol. 18, Iss. 2, 2001-03 ,pp. : 121-130

Humana Press, Inc

Access to resources Recommend Favorite